Clinical Trials
9 trialsNCT07619313 2026-06-04
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT06625320 2026-06-02
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07409272 2026-06-02
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
NCT07621718 2026-06-02
RASolute 305
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT04594772 2026-06-01
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06998940 2026-05-22
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT02890355 2026-05-20
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04421820 2026-05-18
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting